Phathom Pharmaceuticals (PHAT) Analyst & Key Data

Analyst Consensus

Analyst recommendation mix is not available yet.

Total Analysts12

Ratings

Updated Sep 12, 2026

Overall Rating

C

DCF Score1.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score5.0 / 5

Valuation

Current Stock Price

$8.36

Median Target+145.22%

$20.50

Potential upside vs current price

Current Stock Price

$8.36

Median Target+145.22%

$20.50

Potential upside vs current price

Analyst Consensus

Analyst recommendation mix is not available yet.

Total Analysts12

Ratings

Updated Sep 12, 2026

Overall Rating

C

DCF Score1.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score5.0 / 5

Valuation

Current Stock Price

$8.36

Median Target+145.22%

$20.50

Potential upside vs current price

Current Stock Price

$8.36

Median Target+145.22%

$20.50

Potential upside vs current price

Phathom Pharmaceuticals, Inc.